The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients
The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients
复制标题
半乳糖凝集素3在系统性红斑狼疮患者皮肤损伤中的作用
DOI：
10.1177/0961203317736144
复制
发表时间：
2018-04-01
期刊：
影响因子：
2.6
通讯作者：
Wang, L.
中科院分区：
文献类型：
--
作者：
Shi, Z.;Meng, Z.;Wang, L.
目的我们先前的研究表明，抗Galectin-3抗体与系统性红斑狼疮(SLE)狼疮皮损的发生密切相关。本研究旨在探讨Galectin-3在SLE皮肤损伤中的作用。方法系统性红斑狼疮患者49例，皮肌炎患者16例，系统性硬皮病患者11例，正常对照组20例。血清和皮肤分别用ELISA法和免疫组织化学法检测Galectin-3。结果系统性红斑狼疮患者血清Galectin-3水平显著高于皮肌炎组(P <； 0.001)、系统性硬皮病组(P <； 0.001)和健康对照组(P <； 0.001)，而有皮损和无皮损的SLE患者血清Galectin-3水平差异无统计学意义(P = 0.2010)，且与皮肤病活动(r = −0.020，P = 0.93)和皮损评分(r = −0.380，P = 0.09)无关。系统性红斑狼疮、皮肌炎和系统性硬皮病患者皮损中Galectin-3的表达低于健康对照组(P = 0.0055.0 5)，而不同疾病的Galectin-3表达差异无统计学意义(P & 0.0 5)。在系统性红斑狼疮的皮损亚型中，Galectin-3在慢性皮肤红斑狼疮中的表达低于急性皮肤红斑狼疮(P = 0.0439)。结论血清Galectin-3在狼疮皮肤损害的发病机制中可能不起作用，但可作为SLE疾病活动性的潜在生物标志物。与健康对照组相比，狼疮皮损患者的Galectin-3水平大大降低，这可能有助于炎症细胞在皮肤中的募集。
Objective Our previous research suggested that anti-galectin-3 antibody was highly associated with the development of lupus skin lesions in systemic lupus erythematosus (SLE). In this study we aimed to investigate the involvement of galectin-3 in SLE skin damage. Methods The study consisted of 49 patients with SLE, 16 with dermatomyositis and 11 with systemic scleroderma and 20 healthy controls. Galectin-3 was examined by ELISA and immunohistochemical staining in serum and skin, respectively. Results Serum galectin-3 was significantly higher in patients with SLE than in those with dermatomyositis (P < 0.01), systemic scleroderma (P < 0.001) and healthy controls (P < 0.001); however, it was comparable between SLE patients with and without skin lesions (P = 0.2010 and was not correlated with cutaneous disease activity (r = −0.020, P = 0.93) or damage score (r = −0.380, P = 0.09). Galectin-3 expression was reduced in epidermis in lesional skin from patients with SLE, dermatomyositis and systemic scleroderma compared to healthy controls (P = 0.0055), whereas it was comparable among diseases (P > 0.05). As for subtypes of skin lesions in SLE, galectin-3 expression was lower in chronic cutaneous lupus erythematosus than in acute cutaneous lupus erythematosus (P = 0.0439). Conclusion Serum galectin-3 is unlikely to play a role in the pathogenesis of lupus skin damage, but can be a potential biomarker for the measurement of SLE disease activity. Galectin-3 is greatly reduced in patients with lupus lesions compared with healthy controls, which may contribute to the recruitment of inflammatory cells in the skin.